Explore our network

The new CPMS (Clinical Patient Management System) 2.0 is now fully available, offering new features and improvements to enhance the user experience. ERN RARE-LIVER will also be launching the CPMS Live Case Discussion Series, starting in June 2025.

The next ERN RARE-LIVER Online Meeting will take place on 22 October 2025. An official time and information on the agenda will follow shortly. For questions and further details please contact the office.

ERN RARE-LIVER has released its first R-LIVER Newsletter, providing regular updates on the latest data and developments related to the ERN RARE-LIVER registry (R-LIVER). For subscriptions or further information, please contact the ERN Office.

PSC Support is inviting applications (letters of intent initially) for funding for research proposals that address important and novel, basic or clinical research question relating to PSC, PSC-IBD and cholangiocarcinoma in line with the PSC Support Research Strategy.

The ERN RARE-LIVER plans to fund workshops of disease working groups and other initiatives in 2026. We want to especially encourage disease working groups to engage their members through structured workshops and meetings aimed at collaboration and discussion.

As part of a research initiative on de novo autoimmune hepatitis in paediatric and adult transplant patients, physicians are invited to participate in a brief pre-survey. Your expertise and experience in this area is vital to this process.

We are happy to release the updated Wilson disease guideline which is the results of EASL-ERN RARE-LIVER collaborative work with endorsement of ESPGHAN. The value of the guideline is methodology which strictly followed EASL guidelines how to write guidelines. The update introduced several novelties.

Key insights from the ERN RARE-LIVER workshop on healthcare transition, focused on improving the transfer from paediatric to adult care.

Porto-sinusoidal vascular liver disorder (PSVD) is a rare liver condition that often leads to severe complications from portal hypertension and can reduce life expectancy.